Evidence map›Paper›PMID 32023450›Full record

ArticleCell reports2020

Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma.

S John Liu, Stephen T Magill, Harish N Vasudevan, Stephanie Hilz, Javier E Villanueva-Meyer, Sydney Lastella, Vikas Daggubati, Jordan Spatz, Abrar Choudhury, Brent A Orr and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Frontiers in oncology · 2024
    Review
  4. Driver mutations in ADGRL3 are involved in the evolution of ependymoma.Laboratory investigation; a journal of technical methods and pathology · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Harnessing brain development to understand brain tumours.Development (Cambridge, England) · 2021
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

S John LiuDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Stephen T MagillDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Harish N VasudevanDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Stephanie HilzDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.
Sydney LastellaDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Vikas DaggubatiDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Jordan SpatzDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Abrar ChoudhuryDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Brent A OrrDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Benjamin DemareeDepartment of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Kyounghee SeoDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Sean P FerrisDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Adam R AbateDepartment of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Andrew W BollenDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Michael W McDermottDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Joseph F CostelloDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
David R RaleighDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: david.raleigh@ucsf.edu.
University of California, San Francisco · USQB3 · USSt. Jude Children's Research Hospital · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Understanding How Ciliary Hedgehog Signaling Causes MedulloblastomaK08CA212279 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2017 to 2021
$886k
Development of a molecular diagnostic and prognostic signature for meningiomaF32CA213944 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAGILL, STEPHEN T · 2017 to 2017
$63k
NCI NIH HHS F32 CA213944NCI NIH HHS K08 CA212279NIGMS NIH HHS T32 GM007618
6 · The paper itself

Abstract

Ependymomas exist within distinct genetic subgroups, but the molecular diversity within individual ependymomas is unknown. We perform multiplatform molecular profiling of 6 spatially distinct samples from an ependymoma with C11orf95-RELA fusion. DNA methylation and RNA sequencing distinguish clusters of samples according to neuronal development gene expression programs that could also be delineated by differences in magnetic resonance blood perfusion. Exome sequencing and phylogenetic analysis reveal epigenomic intratumor heterogeneity and suggest that chromosomal structural alterations may precede accumulation of single-nucleotide variants during ependymoma tumorigenesis. In sum, these findings shed light on the oncogenesis and intratumor heterogeneity of ependymoma.

Indexed as

EpigenomicsGene Expression ProfilingGenetic HeterogeneityAdultCell DifferentiationCell Line, TumorChromosome AberrationsEpendymomaGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseHumansMaleMutationNeuronsPhylogenyProteinsHistone-Lysine N-MethyltransferaseProteinsSETD2 protein, humanTranscription Factor RelATranscription FactorsZFTA protein, humanbrain tumorC11orf95-RELAcancerDNA methylationependymomaepigenomicsexome sequencingmagnetic resonance imagingRNA sequencingSETD2

Identifiers

PMID32023450
PMCPMC7313374
OpenAlexW3005198602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.